Health Catalyst has been flagged as a stock to sell due to three fundamental weaknesses. The company's billings plateaued at $84.21 million in the latest quarter, signaling challenges in customer acquisition and retention. Its gross margin averaged just 50.4% over the past year, meaning it spent $49.56 on service costs for every $100 in revenue, a level substantially worse than most software businesses. Additionally, the customer acquisition cost payback period turned negative, indicating that incremental sales and marketing investments are outpacing revenue and highlighting intense competitive pressure. The stock has lost 3.6% over the past six months, underperforming the S&P 500's 8.2% gain, and currently trades at 0.7 times forward price-to-sales.
Health Catalyst IncBillings plateaued at $84.21M, signaling customer acquisition and retention challenges.
Amazon.com Inc
PayPal Holdings Inc